The post criticizes investors for applying the AI-infrastructure bottleneck trade to biology, saying disparate life-science businesses are trading as one thematic basket despite differences in their economics. It warns that theme- and hype-driven investing can lead to large drawdowns, without naming specific assets or tickers.